California State Teachers Retirement System Has $5.78 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NEO. Valeo Financial Advisors LLC boosted its holdings in NeoGenomics by 150.0% during the third quarter. Valeo Financial Advisors LLC now owns 1,000 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 600 shares in the last quarter. Fiduciary Planning LLC acquired a new stake in NeoGenomics during the third quarter valued at approximately $41,000. FinTrust Capital Advisors LLC boosted its holdings in NeoGenomics by 27.0% during the third quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 270 shares in the last quarter. Flagship Harbor Advisors LLC boosted its holdings in NeoGenomics by 48.0% during the third quarter. Flagship Harbor Advisors LLC now owns 1,310 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 425 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in NeoGenomics during the third quarter valued at approximately $55,000. 86.09% of the stock is currently owned by institutional investors.
Several research analysts have recently commented on the company. SVB Leerink boosted their target price on NeoGenomics from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, November 20th. Morgan Stanley began coverage on shares of NeoGenomics in a research report on Wednesday, September 9th. They issued an “overweight” rating and a $46.00 price objective for the company. Guggenheim began coverage on shares of NeoGenomics in a research report on Friday, August 28th. They issued a “buy” rating and a $46.00 price objective for the company. Benchmark boosted their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, CIBC upgraded shares of NeoGenomics to an “outperformer” rating and boosted their price objective for the stock from $10.50 to $14.50 in a research report on Monday, October 26th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $40.96.
Shares of NeoGenomics stock opened at $53.62 on Monday. The firm has a fifty day moving average of $45.17 and a two-hundred day moving average of $38.17. The stock has a market capitalization of $5.95 billion, a price-to-earnings ratio of -1,786.74 and a beta of 0.78. NeoGenomics, Inc. has a 52 week low of $20.47 and a 52 week high of $54.39. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.22 and a current ratio of 6.54.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The company had revenue of $125.40 million during the quarter, compared to analyst estimates of $126.23 million. During the same quarter in the previous year, the business earned $0.07 EPS. The firm’s revenue was up 19.8% on a year-over-year basis. As a group, research analysts forecast that NeoGenomics, Inc. will post -0.01 EPS for the current fiscal year.
In other news, Director Bruce K. Crowther sold 2,400 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $35.68, for a total value of $85,632.00. Following the completion of the transaction, the director now owns 46,483 shares of the company’s stock, valued at approximately $1,658,513.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce K. Crowther sold 8,333 shares of the company’s stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $35.01, for a total transaction of $291,738.33. Following the completion of the transaction, the director now directly owns 46,483 shares of the company’s stock, valued at $1,627,369.83. The disclosure for this sale can be found here. Insiders sold a total of 1,045,294 shares of company stock valued at $44,216,163 in the last three months. 6.50% of the stock is owned by company insiders.
NeoGenomics Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source